Limits...
Role of contrast-enhanced ultrasound in evaluating the efficiency of ultrasound guided percutaneous microwave ablation in patients with renal cell carcinoma.

Li X, Liang P, Yu J, Yu XL, Liu FY, Cheng ZG, Han ZY - Radiol Oncol (2013)

Bottom Line: The CEUS results of the third day after the ablation were compared with the synchronous contrast-enhanced computed tomography (CT)/magnetic resonance imaging (MRI) results and biopsy pathological results.The combination of clinical follow-up results and CT/MRI imaging findings was the reference standard of CEUS results for evaluating the therapeutic effect.Among residual tumours, 13 (86.7%) were confirmed by contrast-enhanced CT/MRI findings and biopsy results.

View Article: PubMed Central - PubMed

Affiliation: Interventional Ultrasound Department of Chinese PLA General Hospital, Beijing, China ; Medical College of Nankai University, Tianjin, China.

ABSTRACT

Background: The aim of the study was to evaluate the efficiency and feasibility of contrast-enhanced ultrasound (CEUS) with Sonovue in assessing of renal cell carcinomas (RCCs) following ultrasound (US)-guided percutaneous microwave ablation (MWA).

Patinets and methods: Seventy-nine patients (60 males and 19 females) with 83 lesions (mean size 3.2±1.6 cm) were treated by US-guided percutaneous MWA. The CEUS results of the third day after the ablation were compared with the synchronous contrast-enhanced computed tomography (CT)/magnetic resonance imaging (MRI) results and biopsy pathological results. The follow-up was performed by CEUS and CT/MRI after 1, 3, 6 months and every 6 months subsequently. The combination of clinical follow-up results and CT/MRI imaging findings was the reference standard of CEUS results for evaluating the therapeutic effect. The identification of residual or recurrence tumour was assessed by two blinded radiologists.

Results: On the third day after MWA, CEUS showed 68 of 83 lesions (68/83, 81.9%) successfully ablated and 15 of 83 (18.1%) with residual tumours. Among residual tumours, 13 (86.7%) were confirmed by contrast-enhanced CT/MRI findings and biopsy results. The sensitivity, specificity, accuracy, positive and negative predictive value of CEUS evaluating the short-term MWA effectiveness were 100%, 97.1%, 97.6%, 86.7% and 100%, respectively. During the six years follow-up (median 26 months), the CEUS showed recurrence in 7 patients, and six of them achieved consistent results on CEUS and CT/MRI imaging. The sensitivity, specificity, accuracy, positive and negative predictive value for CEUS evaluating long-term MWA effectiveness were 85.7%, 98.7%, 97.6%, 85.7% and 98.7%, respectively.

Conclusions: The post-procedural CEUS demonstrated as an effective and feasible method in evaluating a therapeutic effect of RCCs following MWA.

No MeSH data available.


Related in: MedlinePlus

Images in 82-year-old female with a 3.9 cm × 3.7 cm renal clear cell carcinoma treated with microwave ablation (MWA). (A) Pre-ablation contrast-enhanced US scan showed one hyper-enhancement lesion exophyticly (arrow). (B) Seven days after ablation contrast-enhanced US showed the whole lesion no-enhancement continuously. (C) Transverse contrast-enhanced multidetector-row CT imaging showed one hyper-intense lesion pre-ablation and hypo-intense one in arterial phase 7 days (D), 1 month (E) and 6 months (F) after ablation.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC3814286&req=5

f1-rado-47-04-398: Images in 82-year-old female with a 3.9 cm × 3.7 cm renal clear cell carcinoma treated with microwave ablation (MWA). (A) Pre-ablation contrast-enhanced US scan showed one hyper-enhancement lesion exophyticly (arrow). (B) Seven days after ablation contrast-enhanced US showed the whole lesion no-enhancement continuously. (C) Transverse contrast-enhanced multidetector-row CT imaging showed one hyper-intense lesion pre-ablation and hypo-intense one in arterial phase 7 days (D), 1 month (E) and 6 months (F) after ablation.

Mentions: On the third day after MWA, CEUS showed that 68 of 83 lesions (82.9%) were successfully ablated. The results of CEUS were confirmed by contrast-enhanced CT/MRI three days after MWA (Figure 1). Fifteen of 83 (18.3%) lesions appeared residual tumour on CEUS. Among them biopsy results verified 13 residual tumours (Figure 2) and the second CEUS-guided ablations were done. The sensitivity, specificity, accuracy, PPV and NPV of CEUS evaluating instant effect of MWA of RCC were 100%, 97.1%, 97.6%, 86.7% and 100%, respectively (Table 2).


Role of contrast-enhanced ultrasound in evaluating the efficiency of ultrasound guided percutaneous microwave ablation in patients with renal cell carcinoma.

Li X, Liang P, Yu J, Yu XL, Liu FY, Cheng ZG, Han ZY - Radiol Oncol (2013)

Images in 82-year-old female with a 3.9 cm × 3.7 cm renal clear cell carcinoma treated with microwave ablation (MWA). (A) Pre-ablation contrast-enhanced US scan showed one hyper-enhancement lesion exophyticly (arrow). (B) Seven days after ablation contrast-enhanced US showed the whole lesion no-enhancement continuously. (C) Transverse contrast-enhanced multidetector-row CT imaging showed one hyper-intense lesion pre-ablation and hypo-intense one in arterial phase 7 days (D), 1 month (E) and 6 months (F) after ablation.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC3814286&req=5

f1-rado-47-04-398: Images in 82-year-old female with a 3.9 cm × 3.7 cm renal clear cell carcinoma treated with microwave ablation (MWA). (A) Pre-ablation contrast-enhanced US scan showed one hyper-enhancement lesion exophyticly (arrow). (B) Seven days after ablation contrast-enhanced US showed the whole lesion no-enhancement continuously. (C) Transverse contrast-enhanced multidetector-row CT imaging showed one hyper-intense lesion pre-ablation and hypo-intense one in arterial phase 7 days (D), 1 month (E) and 6 months (F) after ablation.
Mentions: On the third day after MWA, CEUS showed that 68 of 83 lesions (82.9%) were successfully ablated. The results of CEUS were confirmed by contrast-enhanced CT/MRI three days after MWA (Figure 1). Fifteen of 83 (18.3%) lesions appeared residual tumour on CEUS. Among them biopsy results verified 13 residual tumours (Figure 2) and the second CEUS-guided ablations were done. The sensitivity, specificity, accuracy, PPV and NPV of CEUS evaluating instant effect of MWA of RCC were 100%, 97.1%, 97.6%, 86.7% and 100%, respectively (Table 2).

Bottom Line: The CEUS results of the third day after the ablation were compared with the synchronous contrast-enhanced computed tomography (CT)/magnetic resonance imaging (MRI) results and biopsy pathological results.The combination of clinical follow-up results and CT/MRI imaging findings was the reference standard of CEUS results for evaluating the therapeutic effect.Among residual tumours, 13 (86.7%) were confirmed by contrast-enhanced CT/MRI findings and biopsy results.

View Article: PubMed Central - PubMed

Affiliation: Interventional Ultrasound Department of Chinese PLA General Hospital, Beijing, China ; Medical College of Nankai University, Tianjin, China.

ABSTRACT

Background: The aim of the study was to evaluate the efficiency and feasibility of contrast-enhanced ultrasound (CEUS) with Sonovue in assessing of renal cell carcinomas (RCCs) following ultrasound (US)-guided percutaneous microwave ablation (MWA).

Patinets and methods: Seventy-nine patients (60 males and 19 females) with 83 lesions (mean size 3.2±1.6 cm) were treated by US-guided percutaneous MWA. The CEUS results of the third day after the ablation were compared with the synchronous contrast-enhanced computed tomography (CT)/magnetic resonance imaging (MRI) results and biopsy pathological results. The follow-up was performed by CEUS and CT/MRI after 1, 3, 6 months and every 6 months subsequently. The combination of clinical follow-up results and CT/MRI imaging findings was the reference standard of CEUS results for evaluating the therapeutic effect. The identification of residual or recurrence tumour was assessed by two blinded radiologists.

Results: On the third day after MWA, CEUS showed 68 of 83 lesions (68/83, 81.9%) successfully ablated and 15 of 83 (18.1%) with residual tumours. Among residual tumours, 13 (86.7%) were confirmed by contrast-enhanced CT/MRI findings and biopsy results. The sensitivity, specificity, accuracy, positive and negative predictive value of CEUS evaluating the short-term MWA effectiveness were 100%, 97.1%, 97.6%, 86.7% and 100%, respectively. During the six years follow-up (median 26 months), the CEUS showed recurrence in 7 patients, and six of them achieved consistent results on CEUS and CT/MRI imaging. The sensitivity, specificity, accuracy, positive and negative predictive value for CEUS evaluating long-term MWA effectiveness were 85.7%, 98.7%, 97.6%, 85.7% and 98.7%, respectively.

Conclusions: The post-procedural CEUS demonstrated as an effective and feasible method in evaluating a therapeutic effect of RCCs following MWA.

No MeSH data available.


Related in: MedlinePlus